ADVAIR DISKUS 500 Drug Patent Profile
✉ Email this page to a colleague
When do Advair Diskus 500 patents expire, and when can generic versions of Advair Diskus 500 launch?
Advair Diskus 500 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.
The generic ingredient in ADVAIR DISKUS 500 is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Advair Diskus 500
A generic version of ADVAIR DISKUS 500 was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADVAIR DISKUS 500?
- What are the global sales for ADVAIR DISKUS 500?
- What is Average Wholesale Price for ADVAIR DISKUS 500?
Summary for ADVAIR DISKUS 500
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | ADVAIR DISKUS 500 at DailyMed |
US Patents and Regulatory Information for ADVAIR DISKUS 500
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp Ltd | ADVAIR DISKUS 500/50 | fluticasone propionate; salmeterol xinafoate | POWDER;INHALATION | 021077-003 | Aug 24, 2000 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
